APA (7th ed.) Citation

Chakraborty, A., Diwan, A., Chiniga, V., Arora, V., Thakur, Y., Tatake, J., . . . Holkar, N. (2026). Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential. PLoS ONE, 21(2), 1. https://doi.org/10.1371/journal.pone.0324811

Chicago Style (17th ed.) Citation

Chakraborty, Ashok, Anil Diwan, Vijetha Chiniga, Vinod Arora, Yogesh Thakur, Jayant Tatake, Rajesh Pandey, Preetam Holkar, and Neelam Holkar. "Remdesivir-bisPropionate, a Better Derivative of Remdesivir Against SARS-CoV-2: Comparison of in Vitro and in Vivo PK/PD Study as Well as Its Therapeutic Potential." PLoS ONE 21, no. 2 (2026): 1. https://doi.org/10.1371/journal.pone.0324811.

MLA (9th ed.) Citation

Chakraborty, Ashok, et al. "Remdesivir-bisPropionate, a Better Derivative of Remdesivir Against SARS-CoV-2: Comparison of in Vitro and in Vivo PK/PD Study as Well as Its Therapeutic Potential." PLoS ONE, vol. 21, no. 2, 2026, p. 1, https://doi.org/10.1371/journal.pone.0324811.